PMP22-related disease: A novel splice site acceptor variant and intrafamilial phenotype variability

Gutmann, 2015, Update on Charcot–Marie–Tooth disease, Curr Opin Neurol, 28, 462, 10.1097/WCO.0000000000000237 Nodera, 2003, HNPP due to a novel missense mutation of the PMP22 gene, Neurology, 60, 1863, 10.1212/01.WNL.0000066049.13848.F2 Passage, 2004, Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot–Marie–Tooth disease, Nat Med, 10, 396, 10.1038/nm1023 Meyer zu Horste, 2007, Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy, Ann Neurol, 61, 61, 10.1002/ana.21026 Kawarai, 2016, MFN2 transcripts escaping from nonsense-mediated mRNA decay pathway cause Charcot–Marie–Tooth disease type 2A2, J Neurol Neurosurg Psychiatry, 87, 1263, 10.1136/jnnp-2015-312646 Bird, 1993, Hereditary neuropathy with liability to pressure palsies Leblhuber, 1991, Clinical and electrodiagnostic findings, nerve biopsy and blood group markers in a family with hereditary neuropathy with liability to pressure palsies, Acta Neurol Scand, 83, 166, 10.1111/j.1600-0404.1991.tb04670.x Wang, 2017, PMP22 exon 4 deletion causes ER retention of PMP22 and a gain-of-function allele in CMT1E, Ann Clin Transl Neurol, 4, 236, 10.1002/acn3.395